156 related articles for article (PubMed ID: 32919086)
41. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel.
Funk S; Miller MM; Mishell DR; Archer DF; Poindexter A; Schmidt J; Zampaglione E;
Contraception; 2005 May; 71(5):319-26. PubMed ID: 15854630
[TBL] [Abstract][Full Text] [Related]
42. Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than 1 year.
Morrell KM; Cremers S; Westhoff CL; Davis AR
Contraception; 2016 Mar; 93(3):263-5. PubMed ID: 26577754
[TBL] [Abstract][Full Text] [Related]
43. Prevalence of early discontinuation and associated factors among a retrospective cohort of etonogestrel contraceptive implant users.
Peterson AM; Brown A; Savage A; Dempsey A
Eur J Contracept Reprod Health Care; 2019 Dec; 24(6):475-479. PubMed ID: 31545110
[No Abstract] [Full Text] [Related]
44. A Comparison of Breastfeeding Exclusivity and Duration Rates Between Immediate Postpartum Levonorgestrel Versus Etonogestrel Implant Users: A Prospective Cohort Study.
Krashin JW; Lemani C; Nkambule J; Talama G; Chinula L; Flax VL; Stuebe AM; Tang JH
Breastfeed Med; 2019; 14(1):69-76. PubMed ID: 30508390
[TBL] [Abstract][Full Text] [Related]
45. Intrauterine Contraception Continuation in Adolescents and Young Women: A Systematic Review.
Usinger KM; Gola SB; Weis M; Smaldone A
J Pediatr Adolesc Gynecol; 2016 Dec; 29(6):659-667. PubMed ID: 27386754
[TBL] [Abstract][Full Text] [Related]
46. One-year continuation of the etonogestrel contraceptive implant in women with postabortion or interval placement.
Mark A; Sonalkar S; Borgatta L
Contraception; 2013 Nov; 88(5):619-23. PubMed ID: 23790436
[TBL] [Abstract][Full Text] [Related]
47. An exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users.
Lazorwitz A; Sheeder J; Teal S
Eur J Contracept Reprod Health Care; 2021 Aug; 26(4):323-325. PubMed ID: 33596152
[TBL] [Abstract][Full Text] [Related]
48. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study.
Lazorwitz A; Sheeder J; Teal S
Contraception; 2023 Jul; 123():110035. PubMed ID: 36997081
[TBL] [Abstract][Full Text] [Related]
49. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
Potter LS; Dalberth BT; Cañamar R; Betz M
Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
[TBL] [Abstract][Full Text] [Related]
50. Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: one-year results of an observational study.
Short M; Dallay D; Omokanye S; Hanisch JU; Inki P
Eur J Contracept Reprod Health Care; 2012 Feb; 17(1):79-88. PubMed ID: 22200172
[TBL] [Abstract][Full Text] [Related]
51. Association of Etonogestrel-Releasing Contraceptive Implant with Reduced Weight Gain in an Exclusively Breastfed Infant: Report and Literature Review.
Stuebe AM; Bryant AG; Lewis R; Muddana A
Breastfeed Med; 2016 May; 11(4):203-6. PubMed ID: 27032034
[TBL] [Abstract][Full Text] [Related]
52. Impact of an implantable steroid contraceptive (etonogestrel-releasing implant) on quality of life and sexual function: a preliminary study.
Di Carlo C; Sansone A; De Rosa N; Gargano V; Tommaselli GA; Nappi C; Bifulco G
Gynecol Endocrinol; 2014 Jan; 30(1):53-6. PubMed ID: 24131079
[TBL] [Abstract][Full Text] [Related]
53. Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain.
Arribas-Mir L; Rueda-Lozano D; Agrela-Cardona M; Cedeño-Benavides T; Olvera-Porcel C; Bueno-Cavanillas A
Contraception; 2009 Nov; 80(5):457-62. PubMed ID: 19835720
[TBL] [Abstract][Full Text] [Related]
54. Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy.
Ragazini CS; Bahamondes MV; Prandini TR; Brito MB; Amaral E; Bahamondes L; Duarte G; Quintana SM; Ferriani RA; Vieira CS
Eur J Contracept Reprod Health Care; 2016 Aug; 21(4):285-9. PubMed ID: 27227739
[TBL] [Abstract][Full Text] [Related]
55. Tamoxifen for the treatment of breakthrough bleeding with the etonogestrel implant: a randomized controlled trial.
Simmons KB; Edelman AB; Fu R; Jensen JT
Contraception; 2017 Feb; 95(2):198-204. PubMed ID: 27725164
[TBL] [Abstract][Full Text] [Related]
56. Long-acting reversible contraception in adolescents: a systematic review and meta-analysis.
Diedrich JT; Klein DA; Peipert JF
Am J Obstet Gynecol; 2017 Apr; 216(4):364.e1-364.e12. PubMed ID: 28038902
[TBL] [Abstract][Full Text] [Related]
57. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel.
Davies GC; Feng LX; Newton JR; Van Beek A; Coelingh-Bennink HJ
Contraception; 1993 Mar; 47(3):251-61. PubMed ID: 8462316
[TBL] [Abstract][Full Text] [Related]
58. Long acting reversible contraception in adolescents with cardiovascular conditions.
Amies Oelschlager AM; Micks EA; Debiec KE; Nizamic T; Mantrala MD; Prager SW
J Pediatr Adolesc Gynecol; 2014 Dec; 27(6):353-5. PubMed ID: 25256877
[TBL] [Abstract][Full Text] [Related]
59. Best Practices for Counseling Adolescents about the Etonogestrel Implant.
Berlan ED; Richards MJ; Vieira CS; Creinin MD; Kaunitz AM; Fraser IS; Edelman A; Mansour D
J Pediatr Adolesc Gynecol; 2020 Oct; 33(5):448-454. PubMed ID: 32621879
[TBL] [Abstract][Full Text] [Related]
60. Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant.
Modesto W; Dal Ava N; Monteiro I; Bahamondes L
Arch Gynecol Obstet; 2015 Dec; 292(6):1387-91. PubMed ID: 26088190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
